The content on this site is intended for healthcare professionals only
Dr Malavasi talks to ecancertv at ICMM 2016 about his work looking at CD38 as a target in multiple myeloma.
ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
SIOG 2024: Updates in haematology
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
More effective treatment options required for patients with MM post lenalidomide exposure
Multiple myeloma in a resource constrained setting
